• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    11/22/23 4:31:02 PM ET
    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASMB alert in real time by email

    Gainers

    • Telesis Bio (NASDAQ:TBIO) shares increased by 32.5% to $0.53 during Wednesday's after-market session. The company's market cap stands at $15.8 million.
    • Femasys (NASDAQ:FEMY) shares rose 19.28% to $1.09. The market value of their outstanding shares is at $23.5 million.
    • Axcella Health (NASDAQ:AXLA) shares rose 13.1% to $5.18. The company's market cap stands at $15.2 million.
    • Assembly Biosciences (NASDAQ:ASMB) stock increased by 12.96% to $0.73. The market value of their outstanding shares is at $48.0 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) stock moved upwards by 9.96% to $0.32. The market value of their outstanding shares is at $14.3 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock rose 7.24% to $0.37. The market value of their outstanding shares is at $16.4 million.

    Losers

    • Impel Pharmaceuticals (NASDAQ:IMPL) stock declined by 13.3% to $0.68 during Wednesday's after-market session. The market value of their outstanding shares is at $16.1 million.
    • Gyre Therapeutics (NASDAQ:GYRE) stock decreased by 8.67% to $14.97. The company's market cap stands at $1.1 billion. As per the news, the Q1 earnings report came out yesterday.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock fell 7.63% to $0.28. The market value of their outstanding shares is at $2.4 million.
    • Durect (NASDAQ:DRRX) stock fell 6.16% to $0.61. The company's market cap stands at $18.1 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock decreased by 5.47% to $0.28. The market value of their outstanding shares is at $23.6 million.
    • Aytu BioPharma (NASDAQ:AYTU) shares fell 5.34% to $2.4. The company's market cap stands at $13.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASMB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASMB
    $AXLA
    $AYTU
    $DRRX

    CompanyDatePrice TargetRatingAnalyst
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Gyre Therapeutics Inc.
    $GYRE
    10/10/2025$16.00Buy
    Jefferies
    Assembly Biosciences Inc.
    $ASMB
    9/24/2025$38.00Mkt Outperform
    Citizens JMP
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    Gyre Therapeutics Inc.
    $GYRE
    8/26/2025$18.00Buy
    H.C. Wainwright
    Assembly Biosciences Inc.
    $ASMB
    8/18/2025$50.00Buy
    H.C. Wainwright
    Aytu BioPharma Inc.
    $AYTU
    7/1/2025$8.00Buy
    Lake Street
    Aytu BioPharma Inc.
    $AYTU
    6/30/2025$12.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Jefferies initiated coverage on Gyre Therapeutics with a new price target

    Jefferies initiated coverage of Gyre Therapeutics with a rating of Buy and set a new price target of $16.00

    10/10/25 8:38:16 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Assembly Biosciences with a new price target

    Citizens JMP initiated coverage of Assembly Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

    9/24/25 7:55:39 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Femasys Inc.

    DEF 14A - FEMASYS INC (0001339005) (Filer)

    4/6/26 4:01:10 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)

    4/2/26 4:08:04 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - FEMASYS INC (0001339005) (Filer)

    4/1/26 9:13:11 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

    NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory review.NRx previously received a preliminary determination of bioequivalence for this product.The Company continues to anticipate a decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026. WILMINGTON, Del., April 06, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has received a letter from the Labeling Program of the FDA Office of Generic Drugs whose only comments were limited to min

    4/6/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

    Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its initial clinical Cut-off Study supporting the Company's FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The clinical Cu

    4/2/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Canning John Charles

    4 - FEMASYS INC (0001339005) (Issuer)

    4/1/26 5:31:32 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Canning John Charles

    3 - FEMASYS INC (0001339005) (Issuer)

    4/1/26 5:19:42 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Bjorkquist Jeanette M

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    3/31/26 4:25:04 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

    Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth. As of December 31, 2025, all previously issued convertible debt had been converted into common stock.Anticipated FDA approval of at least one new drug – Preservative Free Ketamine under an ANDA—during Q3 2026. A favorable preliminary bioequivalence determination was received from the FDA last week.A Type C in-person meeting wi

    3/24/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    $AXLA
    $AYTU
    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care